{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:31:09Z","timestamp":1783132269250,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F-CRIN \/French Clinical Research Infrastructure Network"},{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Macular edema (ME) results from hyperpermeability of retinal vessels, leading to chronic extravasation of plasma components into the retina and hence potentially severe visual acuity loss. Current standard of care consists in using intravitreal injections (IVI), which results in a significant medical and economic burden. During diabetic retinopathy (DR) or retinal vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms, also termed TelCaps) for telangiectatic capillaries may play a central role in the onset, early recurrence, and\/or persistence of ME. Since targeted photocoagulation of TelCaps may improve vision, identification, and photocoagulation of TelCaps, it may represent a way to improve management of ME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The Targeted Laser in (Diabetic) Macular Edema (TalaDME) study aims to evaluate whether ICG-guided targeted laser (IGTL), in association with standard of care by IVI, allows reducing the number of injections during the first year of treatment compared with IVI only, while remaining non-inferior for visual acuity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TalaDME is a French, multicentric, two-arms, randomized, sham laser-controlled, double-masked trial evaluating the effect of photocoagulation of TelCaps combined to IVI in patients with ME associated with TelCaps. Patients with vision loss related to center involved ME secondary to RVO or DR and presenting TelCaps are eligible. Two hundred and seventy eyes of 270 patients are randomized in a 1:1 ratio to standard care, i.e., IVI of anti-VEGF solely (control group) or combined with IGTL therapy (experimental group). Stratification is done on the cause of ME (i.e., RVO versus diabetes). Anti-VEGF IVI are administered to both groups monthly for 3\u00a0months (loading dose) and then with a pro re nata regimen with a monthly follow-up for 12\u00a0months. The primary endpoint will be the number of IVI and the change in visual acuity from baseline to 12\u00a0months. Secondary endpoints will be the changes in central macular thickness, impact on quality of life, cost of treatment, and incremental cost-utility ratio in each groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key safety<\/jats:title>\n                    <jats:p>Rare but severe AE linked to the use of IVI and laser, and previously described, are expected. In the sham group, rescue laser photocoagulation may be administered by the unmasked investigator if deemed necessary at month 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The best management of ME associated with TelCaps is debated, and there have been no randomized study designed to answer this question. Given the fact that TelCaps may affect 30 to 60% of patients with chronic ME due to DR or RVO, a large number of patients could benefit from a specific management of TelCaps. TalaDME aims to establish the clinical and medico-economic benefits of additional targeted laser. The results of TalaDME may raise new recommendations for managing ME and impact healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EudraCT: 2018-A00800-55\/ NCT03751501.\u00a0Registration date: Nov. 23, 2018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-07994-1","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T02:02:03Z","timestamp":1713751323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-5223","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Dupas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Castro-Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Eginay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Villeroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Delyfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Giocanti-Auregan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"B\u00e9ral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mesnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chaumet-Riffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Paques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"3","key":"7994_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"9","key":"7994_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/dc15-2171","volume":"39","author":"JL Leasher","year":"2016","unstructured":"Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643\u20139.","journal-title":"Diabetes Care"},{"issue":"9","key":"7994_CR3","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","volume":"21","author":"H King","year":"1998","unstructured":"King H, Aubert RE, Herman WH. Global burden of diabetes, 1995\u20132025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414\u201331.","journal-title":"Diabetes Care"},{"issue":"6","key":"7994_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.diabet.2009.06.002","volume":"35","author":"C Delcourt","year":"2009","unstructured":"Delcourt C, Massin P, Rosilio M. Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population. Diabetes Metab. 2009;35(6):431\u20138.","journal-title":"Diabetes Metab"},{"key":"7994_CR5","doi-asserted-by":"crossref","unstructured":"Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796\u2013806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"issue":"10","key":"7994_CR6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904\u201314.","journal-title":"Ophthalmology"},{"issue":"2","key":"7994_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","volume":"122","author":"MJ Elman","year":"2015","unstructured":"Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375\u201381.","journal-title":"Ophthalmology"},{"issue":"11","key":"7994_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354.","journal-title":"Ophthalmology"},{"key":"7994_CR9","volume":"353","author":"M McCarthy","year":"2016","unstructured":"McCarthy M. Higher priced drugs are not cost effective for diabetic macular edema. US study finds BMJ. 2016;353: i3253.","journal-title":"US study finds BMJ"},{"issue":"8","key":"7994_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888\u201396.","journal-title":"JAMA Ophthalmol"},{"key":"7994_CR11","doi-asserted-by":"crossref","unstructured":"Sun JK, Baker CW, Jampol LM. a step forward in understanding treatment approaches for diabetic macular edema. JAMA Ophthalmol. 2023;141(1):9\u201310.","DOI":"10.1001\/jamaophthalmol.2022.4666"},{"issue":"4","key":"7994_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185\u2013222.","journal-title":"Ophthalmologica"},{"issue":"6","key":"7994_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1120672119857511","volume":"29","author":"L Kodjikian","year":"2019","unstructured":"Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29(6):573\u201384.","journal-title":"Eur J Ophthalmol"},{"key":"7994_CR14","doi-asserted-by":"crossref","unstructured":"Darche M, Verschueren A, Castro Farias D, Borella Y, Paques M. Confocal microscopy of telangiectatic capillaries (TelCaps) and other features of microvascular remodeling following branch retinal vein occlusion. J Anat. 2022; Epub ahead of print","DOI":"10.1111\/joa.13743"},{"issue":"5","key":"7994_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/cxo.12868","volume":"102","author":"R Venkatesh","year":"2019","unstructured":"Venkatesh R, Yadav NK, Bavaharan B, Prabhu V, Sinha S. Multimodal imaging in perifoveal exudative vascular anomalous complex with co-existent diabetic retinopathy. Clin Exp Optom sept. 2019;102(5):528\u201332.","journal-title":"Clin Exp Optom sept"},{"issue":"5","key":"7994_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/aos.14650","volume":"99","author":"LM Smid","year":"2021","unstructured":"Smid LM, Verhoekx JSN, Martinez Ciriano JP, Vermeer KA, Yzer S. Multimodal imaging comparison of perifoveal exudative vascular anomalous complex and resembling lesions. Acta Ophthalmol ao\u00fbt. 2021;99(5):553\u20138.","journal-title":"Acta Ophthalmol ao\u00fbt"},{"issue":"2","key":"7994_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00417-009-1175-6","volume":"248","author":"A Bourhis","year":"2010","unstructured":"Bourhis A, Girmens JF, Boni S, Pecha F, Favard C, Sahel JA, et al. Imaging of macroaneurysms occurring during retinal vein occlusion and diabetic retinopathy by indocyanine green angiography and high resolution optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):161\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"7994_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/bjophthalmol-2019-314355","volume":"104","author":"D Castro Far\u00edas","year":"2019","unstructured":"Castro Far\u00edas D, Matsui Serrano R, Bianchi Gancharov J, de Dios CU, Sahel J, GraueWiechers F, et al. Indocyanine green angiography for identifying telangiectatic capillaries in diabetic macular oedema. Br J Ophthalmol. 2019;104(4):509\u201313.","journal-title":"Br J Ophthalmol"},{"key":"7994_CR19","doi-asserted-by":"crossref","unstructured":"Chaperon M, Kodjikian L, Agard E, Mathis T, Billant J, El-Chehab H, et al. Screening of telangiectatic capillaries in chronic macular edema based on multimodal imaging: a study of 101 eyes. LyoMAC1 study. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2501\u20138.","DOI":"10.1007\/s00417-022-05592-y"},{"issue":"2","key":"7994_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/bjophthalmol-2015-308142","volume":"101","author":"M Paques","year":"2017","unstructured":"Paques M, Philippakis E, Bonnet C, Falah S, Ayello-Scheer S, Zwillinger S, et al. Indocyanine-green-guided targeted laser photocoagulation of capillary macroaneurysms in macular oedema: a pilot study. Br J Ophthalmol. 2017;101(2):170\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"7994_CR21","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41598-022-05950-0","volume":"12","author":"F Datlinger","year":"2022","unstructured":"Datlinger F, Datlinger A, Pollreisz A, Sacu S, Schmidt-Erfurth U, Datlinger P. Intraprocedural OCT monitoring of the immediate treatment response during indocyanine green angiography-guided laser therapy of teleangiectatic capillaries in diabetic macular edema. Sci Rep. 2022;12(1):2315.","journal-title":"Sci Rep"},{"issue":"2","key":"7994_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/IAE.0b013e31821c40a9","volume":"32","author":"T Ueda","year":"2012","unstructured":"Ueda T, Gomi F, Suzuki M, Sakaguchi H, Sawa M, Kamei M, et al. Usefulness of indocyanine green angiography to depict the distant retinal vascular anomalies associated with branch retinal vein occlusion causing serous macular detachment. Retina. 2012;32(2):308\u201313.","journal-title":"Retina"},{"issue":"3","key":"7994_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000437360","volume":"234","author":"S Ogura","year":"2015","unstructured":"Ogura S, Yasukawa T, Kato A, Kuwayama S, Hamada S, Hirano Y, et al. Indocyanine green angiography-guided focal laser photocoagulation for diabetic macular edema. Ophthalmologica. 2015;234(3):139\u201350.","journal-title":"Ophthalmologica"},{"issue":"3","key":"7994_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10384-019-00662-x","volume":"63","author":"M Nozaki","year":"2019","unstructured":"Nozaki M, Kato A, Yasukawa T, Suzuki K, Yoshida M, Ogura Y. Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2019;63(3):243\u201354.","journal-title":"Jpn J Ophthalmol"},{"key":"7994_CR25","doi-asserted-by":"crossref","unstructured":"Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18\u201329.","DOI":"10.7326\/M13-0768"},{"issue":"9","key":"7994_CR26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201\u201310.","journal-title":"Ophthalmology"},{"key":"7994_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/OPTH.S60893","volume":"8","author":"S Kiss","year":"2014","unstructured":"Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611\u201321.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"7994_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","volume":"139","author":"MG Maguire","year":"2021","unstructured":"Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, et al. Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial. JAMA Ophthalmol. 2021;139(12):1266\u201373.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"7994_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11892-016-0815-6","volume":"16","author":"BJ Song","year":"2016","unstructured":"Song BJ, Aiello LP, Pasquale LR. Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep. 2016;16(12):124.","journal-title":"Curr Diab Rep"},{"issue":"4","key":"7994_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.diabet.2017.09.007","volume":"44","author":"Y Jung","year":"2018","unstructured":"Jung Y, Han K, Park HYL, Park CK. Type 2 diabetes mellitus and risk of open-angle glaucoma development in Koreans: An 11-year nationwide propensity-score-matched study. Diabetes Metab. 2018;44(4):328\u201332.","journal-title":"Diabetes Metab"},{"issue":"12","key":"7994_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/bjophthalmol-2013-304564","volume":"98","author":"M Bolz","year":"2014","unstructured":"Bolz M, Lammer J, Deak G, Pollreisz A, Mitsch C, Scholda C, et al. SAVE: a grading protocol for clinically significant diabetic macular oedema based on optical coherence tomography and fluorescein angiography. Br J Ophthalmol. 2014;98(12):1612\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"7994_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/tvst.6.2.7","volume":"6","author":"MJ Allingham","year":"2017","unstructured":"Allingham MJ, Mukherjee D, Lally EB, Rabbani H, Mettu PS, Cousins SW, et al. A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema: a pilot study. Transl Vis Sci Technol. 2017;6(2):7.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"7994_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ajo.2012.12.005","volume":"155","author":"SN Lee","year":"2013","unstructured":"Lee SN, Chhablani J, Chan CK, Wang H, Barteselli G, El-Emam S, et al. Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. Am J Ophthalmol. 2013;155(5):905\u201312.","journal-title":"Am J Ophthalmol"},{"key":"7994_CR34","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203.","DOI":"10.1056\/NEJMoa1414264"},{"key":"7994_CR35","doi-asserted-by":"crossref","unstructured":"Zafar S, Walder A, Virani S, Biggerstaff K, Orengo-Nania S, Chang J, et al. Systemic adverse events among patients with diabetes treated with intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2023;141(7):658\u201366.","DOI":"10.1001\/jamaophthalmol.2023.2098"},{"issue":"2","key":"7994_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hec.584","volume":"10","author":"AH Briggs","year":"2001","unstructured":"Briggs AH, O\u2019Brien BJ. The death of cost-minimization analysis? Health Econ. 2001;10(2):179\u201384.","journal-title":"Health Econ"},{"issue":"4","key":"7994_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","volume":"38","author":"LF Andrade","year":"2020","unstructured":"Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French value set for the EQ-5D-5L. Pharmacoeconomics. 2020;38(4):413\u201325.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"7994_CR38","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","volume":"12","author":"MC Weinstein","year":"2009","unstructured":"Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5\u20139.","journal-title":"Value Health"},{"issue":"8","key":"7994_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jval.2020.04.001","volume":"23","author":"B T\u00e9hard","year":"2020","unstructured":"T\u00e9hard B, Detournay B, Borget I, Roze S, De Pouvourville G. Value of a QALY for France: a new approach to propose acceptable reference values. Value Health. 2020;23(8):985\u201393.","journal-title":"Value Health"},{"key":"7994_CR40","doi-asserted-by":"crossref","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","DOI":"10.1002\/sim.4067"},{"issue":"4","key":"7994_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00417-014-2729-9","volume":"253","author":"JY Shin","year":"2015","unstructured":"Shin JY, Byeon SH, Kwon OW. Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2015;253(4):527\u201335.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"7994_CR42","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/IAE.0000000000002406","volume":"39","author":"RF Spaide","year":"2019","unstructured":"Spaide RF, Barquet LA. Retinal capillary macroaneuvrysms. Retina. 2019;39(10):1889\u201395.","journal-title":"Retina"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-07994-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T02:09:09Z","timestamp":1713751749000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-07994-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7994"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-07994-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2781241\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Trial registration number: EudraCT: 2018-A00800-55. Original document is provided as an additional file.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of images from enrolled patients has been obtained, and original consent form is provided as an additional file.Any written or oral communication of the results of the study must have been previously agreed by the coordinating investigator and, if necessary, by any committee constituted for the study and must be conveyed to the sponsor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"273"}}